Vaccines for preventing hepatitis B in health-care workers (Q24245861)

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

Hepatitis B Immune Globulin for Accidental Exposures among Medical Personnel: Final Report of a Multicenter Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

Hepatitis B Immune Globulin in Prevention of Hepatitis B among Hospital Staff Members

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

Hepatitis B vaccines in patients with chronic renal failure before dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B vaccine responsiveness in Connecticut public safety personnel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B vaccination for patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B prophylaxis for newborns of hepatitis B surface antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in taiwan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Inactivation of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Low-dose (2 micrograms) hepatitis B vaccination in medical students: comparable immunogenicity for intramuscular and intradermal routes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Low-cost hepatitis B vaccine improves uptake among self-paying health-care students

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Intramuscular versus subcutaneous injection for hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Intradermal and intramuscular route for vaccination against hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B: global importance and need for control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Intradermal hepatitis B vaccination in a large hospital employee population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Serious hepatitis B vaccine adverse reactions, are they immune-mediated?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Comparison of three different schedules of vaccination against hepatitis B in health care workers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Influence of smoking on immunological responses to hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Role of aluminium in skin reactions after diphtheria-tetanus-pertussis-poliomyelitis vaccination: an experimental study in rabbits

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Production and immunological analysis of recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Prevention of hepatitis B infection in health care workers after accidental exposure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Persistence of specific antibodies after hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Major adverse reactions to yeast-derived hepatitis B vaccines--a review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Over a decade of experience with a yeast recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B vaccine -- do we need boosters?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Clinical experience with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Intramuscular or intralipomatous injections?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

The modern landscape of transfusion-related iatrogenic Creutzfeldt-Jakob disease and blood screening tests

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Long-term follow-up of hepatitis B vaccination in susceptible hospital personnel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Interaction revisited: the difference between two estimates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

Immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021

[The optimization of the use of economic resources for vaccination against hepatitis B in professionals in the health area]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000100.PUB3

7 January 2021